AB.PA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 11:35):

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines...

Stats
Today's Volume	50 150.00
Average Volume	158 711
Market Cap	102.48M
EPS	€0 ( 2023-09-28 )
Next earnings date	( €0 ) 2024-04-29
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-5.47
ATR14	€0.00400 (0.20%)

Volume Correlation

Long: 0.22 (neutral)

Short: -0.67 (moderate negative)

Signal:(55.559) Neutral

AB Science SA Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

AB Science SA Correlation - Currency/Commodity

0.06
( neutral )

-0.48
( neutral )

0.00
( neutral )

0.51
( weak )

-0.85
( strong negative )

0.03
( neutral )

AB Science SA Financials

Annual	2022
Revenue:	€958 000
Gross Profit:	€927 000 (96.76 %)
EPS:	€-0.290

Q2	2023
Revenue:	€448 000
Gross Profit:	€-1.08M (-241.96 %)
EPS:	€-0.220

Q4	2022
Revenue:	€329 000
Gross Profit:	€329 000 (100.00 %)
EPS:	€-0.140

Q2	2022
Revenue:	€629 000
Gross Profit:	€-71 000.00 (-11.29 %)
EPS:	€-0.150

Financial Reports:

No articles found.

AB Science SA

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.